The reason for our different conclusions may be that not all patients recruited in the studies above received NAC, and that not all studies stratified patients with specific HR+ subtypes for analysis; all of the subjects in our research had HR+ and HER2− BC and underwent NAC. Here, ERBB2 is linked to breast cancer.